Search Results
Found 2 results
510(k) Data Aggregation
(257 days)
Caph sol is indicated for dryness of the mouth or throat (hyposalivation, xerostomia), regardless of the cause and regardless of whether the conditions are temporary or permanent. Caphosol is also indicated as an adjunct to standard oral care in treating the mucositis that may be caused by and increating or high dose chemotherapy. Relief of dryness of the oral mucosa in these conditions is assoc iated with an amelioration of pain.
Capt osol may be used for relief of dryness of the oral mucosa when hyposalivation results from the f )llowing: surgery, radiotherapy near the salivary glands, chemotherapy; infection of dysf inction of the salivary glands; inflammation of the mouth or throat; fever; emotional fact rs such as fear or anxiety; obstruction of the salivary ducts; Sjögren's syndrome; and Bell's Pals /.
Cap 10sol is also indicated for dryness of the oral mucosa due to drugs such as antihistamines or atro ine or other anticholinergic agents that suppress salivary secretion.
It may be used as part of an oral hygiene program for patients with dry mouth. Caphosol provides intensive hygiene of the oral cavity, and may be used to help relieve bad taste and to relieve offensive nasal discharge and crusting.
Caphosol is an clectrolyte solution resembling human saliva, designed in part to replace the normal ionic and pH balance in the oral cavity. It is intended as a mouth rinse to moisten, lubricate, and clean the oral cavity including the mucosa of the mouth, tongue and throat. Caphosol maintains moistness in the oral cavity. It relieves diffuse dryness and fissuring of the oral mucosa, as well as painful tongue conditions due to hyposalivation. Patients having this condition are also prome to dental caries and candidal infections.
Caphosol is a partial substitute for natural saliva. Caphosol facilitates chewing and speaking; loosens tough mucus; prevent mucous membrancs from sticking together; helps remove nasal crust and relieve nasal soreness; improves adherence of dentures, and also relieves bad taste. The purpose of this premarket notification is to expand the claims for Caphosol to allow Caphosol to be marketed as an adjunct to standard oral care for treating the mucositis that may be mansed by radiation or high dose chemotherapy. Relief of dryness of the oral mucosa in these conditions is associated with an amelioration of pain.
Caphosol is a preparation comprising two separately packaged aqueous solutions, a phosphate solution (Caphosol A) and a calcium solution (Caphosol B) which when both ampoule solutions are combined in equal volumes form a solution supersaturated with respect to both calcium and phosphate ions. The solution after mixing the contents of solutions A and B contains:
| Ingredient: | % w/w |
|---|---|
| Dibasic Sodium Phosphate | 0.032 |
| Monobasic Sodium Phosphate | 0.009 |
| Calcium Chloride | 0.052 |
| Sodium Chloride | 0.569 |
| Purified Water | qs ad |
The provided text is for a 510(k) premarket notification for a medical device (Caphosol Artificial Saliva) and describes its intended use, comparison to a predicate device, and the FDA's substantial equivalence determination. It does not contain any information about acceptance criteria or a study proving that the device meets such criteria.
The document is a regulatory submission for a device, which typically focuses on demonstrating substantial equivalence to a previously cleared device, rather than presenting new clinical study data with performance criteria. The FDA letter explicitly states: "We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices..." This indicates that the clearance is based on similarity to an existing device, not on new clinical performance data against specific acceptance criteria.
Therefore, I cannot provide the requested information from the given text. All the fields regarding acceptance criteria, study details, sample sizes, expert qualifications, and ground truth are not present in the provided document.
Ask a specific question about this device
(62 days)
Caphosol is indicated for dryness of the mouth or throat (hyposalivation, xerostomia), regardless of the cause and regardless of whether the condition is temporary or permanent.
Caphosol is indicated for relief of dryness of the oral mucosa when hyposalivation results from the following: surgery, radiotherapy near the salivary glands, chemotherapy, infection or dysfunction of the salivary glands; inflammation of the mouth or throat; fever; emotional factors such as fear or anxiety, obstruction of the salivary ducts, Sjögren's syndrome; and Bell's Palsy.
Caphosol is also indicated for dryness of the oral mucosa due to drugs such as antihistamines or atropine or other anticholinergic agents that suppress salivary secretion.
It may be used as part of an oral hygiene program for patients with dry mouth. Caphosol provides intensive hygiene of the oral cavity, and may be used to help relieve bad taste and to relieve offensive nasal discharge and crusting.
Caphosol™ Artificial Saliva Consisting of a mixture of two solutions Caphosol™ A -- 15 mL Phosphate Solution and Caphosol™ B - 15 mL Calcium Solution
Based on the provided text, there is no information available to answer the specific questions about the acceptance criteria and the study that proves the device meets them.
The document is a 510(k) summary for "Caphosol™ Artificial Saliva," which primarily focuses on establishing substantial equivalence to a predicate device (GLANDOSANE (SALIVART®)). It outlines the device's name, classification, predicate device, and indications for use.
The document does not contain:
- Any specific acceptance criteria for the device's performance.
- Details of a study conducted to demonstrate that the device meets such criteria.
- Information regarding sample sizes, data provenance, expert involvement, adjudication methods, or MRMC studies.
- Results of a standalone algorithm performance study (as this is an artificial saliva, not an AI/algorithm-driven device).
- Details about the ground truth for training or testing sets.
Therefore, I cannot provide the requested table or answer the specific questions based on the provided text.
Ask a specific question about this device
Page 1 of 1